DealForma Research

Recent Articles

Cancer R&D Partnerships, M&A, Venture Funding and IPO Activity – Q2 2026 Review

September 3, 2026

Antibody (Including ADC and DAC) R&D Partnerships, M&A, Ventures & IPOs – H1 2026

August 31, 2026

AI / Machine Learning R&D, M&A, Ventures & IPOs – H1 2026 Review

August 21, 2026

MedTech, Device, Digital Health and Wearables M&A – H1 2026 Review

August 18, 2026

Biopharma Therapeutics and Platforms IPO Activity, Follow-ons and PIPEs – Q2 2026 Review

August 6, 2026

Biopharma Therapeutics and Platforms Venture Funding – Q2 2026 Review

August 4, 2026

Biopharma Therapeutics and Platforms M&A – Q2 2026 Review

July 24, 2026

Biopharma Therapeutics and Platforms R&D Partnerships – Q2 2026 Review

July 20, 2026

Global Healthcare and Life Sciences – Q2 2026 Review

July 8, 2026

Endocrine/Metabolic R&D Partnerships, Venture Funding and IPO Activity – Q1 2026 Review

July 8, 2026

Cardiovascular R&D Partnerships, M&A and Venture Funding – Q1 2026 Review

June 24, 2026

Autoimmune R&D Partnerships, M&A and Venture Funding – Q1 2026 Review

June 23, 2026

What is big pharma buying?

June 16, 2026

All of this by stage, disease indication, modality, target…

+ 0 k

Licensing Deals

+ 0 k

M&A

+ 0 k

Other Deals

+ 0 k

Funding Rounds

+ 0 k

Company Profiles

+ 0 k

Drug Sales Figures